Syndax Pharmaceuticals Stock (NASDAQ:SNDX), Analyst Ratings, Price Targets, Predictions

29d ago, source: Benzinga.com

There is no last upgrade for Syndax Pharmaceuticals.

Syndax Pharmaceuticals Inc SNDX

7d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA

28d ago, source: Zacks.com on MSN

Syndax Pharmaceuticals currently has a Zacks Rank #3 (Hold). Syndax Pharmaceuticals, Inc. price-consensus-chart | Syndax ...

Assessing the Risk and Potential of Syndax Pharmaceuticals Inc’s (SNDX) Stock

8d ago, source: newsheater

Based on Syndax Pharmaceuticals Inc (SNDX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -98.23. The debt to equity ...

Buy Rating Affirmed for Syndax Pharmaceuticals Amidst Strong Clinical Results and Strategic Growth Prospects

17d ago, source:

In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on Syndax Pharmaceuticals (SNDX – Research Report), ...

First Week of June 21st Options Trading For Syndax Pharmaceuticals (SNDX)

6d ago, source: Nasdaq

Investors in Syndax Pharmaceuticals Inc (Symbol: SNDX) saw new options become available this week, for the June 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

Syndax Pharmaceuticals gets grant for inhibitors of menin-mll interaction for cancer treatment

10d ago, source: Pharmaceutical Technology

Discover how Syndax Pharmaceuticals' patent for menin inhibitors could revolutionize leukemia treatment. Formula 0 targets MLL fusion proteins for better outcomes.

Syndax Pharmaceuticals, Inc.: Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

20d ago, source: Finanznachrichten

Syndax Contact Sharon Klahre Syndax Pharmaceuticals, Inc. [email protected] Tel 781.684.9827 SOURCE Syndax Pharmaceuticals, Inc. Großer Dividenden-Report 2024 von Dr. Dennis Riedl Der kostenlose ...

Syndax Pharmaceuticals Inc.

29d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...